Intraprocedural C‐arm dual‐phase cone‐beam enhancement patterns correlate with tumor absorbed dose after radioembolization

• Published in: Medical physics (Lancaster) Vol. 51; no. 4; pp. 3045 - 3052
• Main Authors: Bastiaannet, Remco, Lin, MingDe, Frey, Eric C., Jong, Hugo W. A. M.
• Format: Journal Article
• Language: English
• Published: United States 01.04.2024
• Subjects: cone‐beam CT; contrast‐enhancement; dosimetry; perfusion; radioembolization; radioembolization; contrast-enhancement; perfusion; dosimetry; cone-beam CT
• ISSN: 0094-2405; 2473-4209
• DOI: 10.1002/mp.16882

Background Recent studies have shown a clear relationship between absorbed dose and tumor response to treatment after hepatic radioembolization. These findings help to create more personalized treatment planning and dosimetry. However, crucial to this goal is the ability to predict the dose distribution prior to treatment. The microsphere distribution is ultimately determined by (i) the hepatic vasculature and the resulting blood flow dynamics and (ii) the catheter position. Purpose To show that pretreatment, intra‐procedural imaging of blood flow patterns, as quantified by catheter‐directed intra‐arterial contrast enhancement, correlate with posttreatment microsphere accumulation and, consequently, absorbed dose. Materials and methods Patients who participated in a clinical trial (NCT01177007) and for whom both a pretreatment dual‐phase contrast‐enhanced cone‐beam CT (CBCT) and a posttreatment 90Y PET/CT scan were available were included in this retrospective study. Tumors and perfused volumes were manually delineated on the CBCT by an experienced radiologist. The mean, sum, and standard deviation of the voxels in each volume were recorded. The delineations were transferred to the PET‐based absorbed dose maps by coregistration of the corresponding CTs. Linear multiple regression was used to correlate pretreatment CBCT enhancement to posttreatment 90Y PET/CT‐based absorbed dose in each region. Leave‐one‐out cross‐validation and Bland–Altman analyses were performed on the predicted versus measured absorbed doses. Results Nine patients, with a total of 23 tumors were included. All presented with hepatocellular carcinoma (HCC). Visually, all patients had a clear correspondence between CBCT enhancement and absorbed dose. The correlation between CBCT enhancement and posttherapy absorbed tumor dose based was strong (R2 = 0.91), and moderate for the non‐tumor liver tissue (R2 = 0.61). Limits of agreement were approximately ±55 Gray for tumor tissue. Conclusion There is a linear relationship between pretreatment blood dynamics in HCC tumors and posttreatment absorbed dose, which, if shown to be generalizable, allows for pretreatment tumor absorbed dose prediction.